What is Confluence Discovery Technologies?
Founded in 2010 and headquartered in St. Louis, Missouri, Confluence Discovery Technologies operates as a specialized B2B pharmaceutical entity. The firm distinguishes itself through a dual-focus model: providing high-level drug discovery services and offering expert consulting to navigate the complexities of pharmaceutical development. By integrating deep scientific research with commercial application, the company serves as a critical partner for organizations seeking to streamline their path to market. Its presence across multiple locations allows it to tap into diverse talent pools, fostering an environment of continuous innovation that addresses unmet needs in the health and life sciences industries.
How much funding has Confluence Discovery Technologies raised?
Confluence Discovery Technologies has raised a total of $11.2M across 3 funding rounds:
Series A
$4M
Unspecified
$2.4M
Private Equity
$4.8M
Series A (2012): $4M with participation from BioGenerator, Helix Funds, Missouri Technology, and DFJ Mercury
Unspecified (2015): $2.4M led by Epidarex Capital, BioGenerator, St Louis Arch Angels, Mercury Fund, and Missouri Technology
Private Equity (2016): $4.8M, investors not publicly disclosed
Key Investors in Confluence Discovery Technologies
BioGenerator
Based in St. Louis, Missouri, BioGenerator creates and grows innovative companies through its two complementary approaches, investing through BioGenerator Ventures and comprehensive startup support through BioGenerator Labs.
Epidarex Capital
Epidarex is a transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs, led by a team of early-stage investors who act as trusted partners to founders.
St Louis Arch Angels
A network of accredited investors dedicated to funding early-stage businesses in the St. Louis region, comprising experienced business leaders, engineers, and scientists committed to fostering regional economic growth.
What's next for Confluence Discovery Technologies?
Looking ahead, Confluence Discovery Technologies is well-positioned to capitalize on the increasing demand for outsourced pharmaceutical R&D. With the backing of institutional investors and a proven track record in scientific excellence, the company is expected to prioritize the expansion of its proprietary research platforms and the deepening of its client relationships. The strategic deployment of its recent capital will likely focus on enhancing its technological infrastructure and scaling its consulting operations to meet the evolving requirements of the global biotech market. As the firm continues to mature, its ability to bridge the gap between academic research and commercial pharmaceutical solutions will remain its primary competitive advantage in an increasingly complex regulatory and scientific environment.
See full Confluence Discovery Technologies company page
